

World Journal of *Gastroenterology*

World J Gastroenterol 2023 June 14; 29(22): 3385-3573



REVIEW

- 3385 Overview of current detection methods and microRNA potential in *Clostridioides difficile* infection screening

Bocchetti M, Ferraro MG, Melisi F, Grisolia P, Scrima M, Cossu AM, Yau TO

- 3400 Epidemiology of small intestinal bacterial overgrowth

Efremova I, Maslennikov R, Poluektova E, Vasilieva E, Zharikov Y, Suslov A, Letyagina Y, Kozlov E, Levshina A, Ivashkin V

ORIGINAL ARTICLE

Basic Study

- 3422 Mechanism of annexin A1/N-formylpeptide receptor regulation of macrophage function to inhibit hepatic stellate cell activation through Wnt/ β -catenin pathway

Fan JH, Luo N, Liu GF, Xu XF, Li SQ, Lv XP

- 3440 Study of the roles of caspase-3 and nuclear factor kappa B in myenteric neurons in a P2X7 receptor knockout mouse model of ulcerative colitis

Magalhães HIR, Machado FA, Souza RF, Caetano MAF, Figliuolo VR, Coutinho-Silva R, Castelucci P

- 3469 Comparative analysis of the gut microbiota of wild adult rats from nine district areas in Hainan, China

Niu LN, Zhang GN, Xuan DD, Lin C, Lu Z, Cao PP, Chen SW, Zhang Y, Cui XJ, Hu SK

Case Control Study

- 3482 Plasma exosomal hsa_circ_0079439 as a novel biomarker for early detection of gastric cancer

Li X, Lin YL, Shao JK, Wu XJ, Li X, Yao H, Shi FL, Li LS, Zhang WG, Chang ZY, Chai NL, Wang YL, Linghu EQ

Retrospective Cohort Study

- 3497 Per-oral endoscopic myotomy is safe and effective for pediatric patients with achalasia: A long-term follow-up study

Bi YW, Lei X, Ru N, Li LS, Wang NJ, Zhang B, Yao Y, Linghu EQ, Chai NL

Retrospective Study

- 3508 Efficacy and safety of modified tetracycline dosing in a quadruple therapy for *Helicobacter pylori*: A retrospective single center study

Sun YC, Zhu MJ, Chen XQ, Yue L, Zhao YR, Wang XJ, Kim JJ, Du Q, Hu WL

Observational Study

- 3519 Pre-transjugular-intrahepatic-portosystemic-shunt measurement of hepatic venous pressure gradient and its clinical application: A comparison study

Wang XX, Yin XC, Gu LH, Guo HW, Cheng Y, Liu Y, Xiao JQ, Wang Y, Zhang W, Zou XP, Wang L, Zhang M, Zhu-Ge YZ, Zhang F

- 3534** Difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis

Xu YF, Hao YX, Ma L, Zhang MH, Niu XX, Li Y, Zhang YY, Liu TT, Han M, Yuan XX, Wan G, Xing HC

Prospective Study

- 3548** Prospective study comparing hepatic steatosis assessment by magnetic resonance imaging and four ultrasound methods in 105 successive patients

Collin R, Magnin B, Gaillard C, Nicolas C, Abergel A, Buchard B

SCIENTOMETRICS

- 3561** Research trends on artificial intelligence and endoscopy in digestive diseases: A bibliometric analysis from 1990 to 2022

Du RC, Ouyang YB, Hu Y

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Wolfgang Kreisel, MD, Emeritus Professor, Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, Faculty of Medicine, Medical Center-University of Freiburg, Hugstetter Str. 55, Freiburg 79106, Germany. Wolfgang.Kreisel@uniklinik-freiburg.de

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

June 14, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Overview of current detection methods and microRNA potential in *Clostridioides difficile* infection screening

Marco Bocchetti, Maria Grazia Ferraro, Federica Melisi, Piera Grisolia, Marianna Scrima, Alessia Maria Cossu, Tung On Yau

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Lopitz-Otsoa F, Spain; Zhou B, China

Received: January 25, 2023

Peer-review started: January 25, 2023

First decision: March 15, 2023

Revised: March 23, 2023

Accepted: May 4, 2023

Article in press: May 4, 2023

Published online: June 14, 2023



Marco Bocchetti, Federica Melisi, Piera Grisolia, Alessia Maria Cossu, Department of Precision Medicine, University of Campania "Luigi Vanvitelli," Naples 80138, Italy

Marco Bocchetti, Federica Melisi, Piera Grisolia, Marianna Scrima, Alessia Maria Cossu, Department of Molecular Oncology, Precision Medicine Laboratory and COVID19 Laboratory, Biogem Scarl, Ariano Irpino 83031, Italy

Maria Grazia Ferraro, School of Infection and Immunity, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom

Maria Grazia Ferraro, Department of Pharmacy, School of Medicine and Surgery, University of Naples "Federico II," Naples 80131, Italy

Tung On Yau, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, United Kingdom

Tung On Yau, Department of Rural Land Use, Scotland's Rural College, Aberdeen AB21 9YA, Scotland, United Kingdom

Tung On Yau, Department of Health Science, University of the People, Pasadena, CA 9110112, United States

Corresponding author: Tung On Yau, BSc, MSc, PhD, Instructor, Lecturer, Researcher, School of Science and Technology, Nottingham Trent University, Clifton Lane, Clifton, Nottingham NG11 8NS, United Kingdom. payton.yau@ntu.ac.uk

Abstract

Clostridioides difficile (formerly called *Clostridium difficile*, *C. difficile*) infection (CDI) is listed as an urgent threat on the 2019 antibiotic resistance threats report in the United States by the Centers for Disease Control and Prevention. Early detection and appropriate disease management appear to be essential. Meanwhile, although the majority of cases are hospital-acquired CDI, community-acquired CDI cases are also on the rise, and this vulnerability is not limited to immunocompromised patients. Gastrointestinal treatments and/or gastrointestinal tract surgeries may be required for patients diagnosed with digestive diseases. Such treatments could suppress or interfere with the patient's immune system and disrupt gut flora homeostasis, creating a suitable microecosystem for *C. difficile* overgrowth. Currently, stool-based non-invasive screening is the first-line approach to CDI

diagnosis, but the accuracy is varied due to different clinical microbiology detection methods; therefore, improving reliability is clearly required. In this review, we briefly summarised the life cycle and toxicity of *C. difficile*, and we examined existing diagnostic approaches with an emphasis on novel biomarkers such as microRNAs. These biomarkers can be easily detected through non-invasive liquid biopsy and can yield crucial information about ongoing pathological phenomena, particularly in CDI.

Key Words: *Clostridioides difficile*; microRNA; Diagnostic; Prognostic; Biomarker

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: *Clostridioides difficile* infection (CDI) is listed as an urgent threat, and early detection and appropriate disease management from hospital-acquired or community-acquired CDI appear to be essential. Currently, stool-based non-invasive screening is the first-line approach to CDI diagnosis, but the accuracy is varied due to different clinical microbiology detection methods. Therefore, improving reliability is clearly required. This review summarised the life cycle and toxicity of *Clostridioides difficile* and examined existing diagnostic potentials on microRNA as novel biomarkers. MicroRNAs can be easily detected through non-invasive liquid biopsy and can yield crucial information about ongoing pathological phenomena, particularly in CDI.

Citation: Bocchetti M, Ferraro MG, Melisi F, Grisolia P, Scrima M, Cossu AM, Yau TO. Overview of current detection methods and microRNA potential in *Clostridioides difficile* infection screening. *World J Gastroenterol* 2023; 29(22): 3385-3399

URL: <https://www.wjgnet.com/1007-9327/full/v29/i22/3385.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v29.i22.3385>

INTRODUCTION

Clostridioides difficile (formerly called *Clostridium difficile*, *C. difficile*) infection (CDI) was classified as an urgent threat in the 2019 antibiotic resistance report in the United States by the Centers for Disease Control and Prevention. Early detection and disease management are urgently needed to reduce public health spending[1]. In addition, of those infected with a medically-related CDI, 1 in 11 people over the age of 65 dies within a month[2]. The acute inflammation caused by the bacteria triggers cytokine production, neutrophil recruitment, mucosal permeability and fluid secretion, leading to colonic tissue damage, nasal diarrhoea and colitis[3,4], which is similar to inflammatory bowel disease[5].

Presently, although most cases are hospital-acquired CDI, community-acquired CDI cases are rising in frequency[6]. Exposure to *C. difficile* in the community might come from various factors, including pets, water, soil, livestock, farms, food processing and production[7]. Previous studies focused on the hospitalisation length and indicated that environmental exposure to animals would be associated with a greater possibility of *C. difficile* colonisation[8]. A population-based study in India found that the composition of the gut microbiota was primarily associated with several geographical factors rather than body mass index and that these changes extended to circulating immunometabolic profiles such as serum N-glycans, immunoglobulins and short-chain fatty acid profiles[9]. These factors may also affect the infection rate.

Once patients have been diagnosed with digestive diseases, gastrointestinal treatments, including gastric-acid suppressing agents, broad-spectrum antibiotics, chemotherapy and/or gastrointestinal tract surgery may be required[10,11]. Such therapies could suppress or interfere with the patient's immune system and disrupt gut flora homeostasis, creating a suitable microecosystem for *C. difficile* overgrowth[12]. Antibiotics such as metronidazole, vancomycin and fidaxomicin have been approved for treatment of patients with CDI, while *C. difficile* strains resistant to various antibiotics have been reported that do not respond to the treatments[13-15]. Faecal microbiota transplantation (FMT) is an alternative treatment strategy for CDI patients; however, it is still in clinical trials because of the treatment safety concern[16].

To date, there are several diagnostic methods for CDI in medical laboratories. However, due to technical limitations and the difficulty of distinguishing symptomatic infections from asymptomatic *C. difficile* colonisation, the accuracy and turnaround time of the test varies[17]. As a result, searching for better tools may increase the accuracy of the detection. In this light, microRNA (miRNA) expression profiling can be helpful for prognosis and diagnosis.

This article reviewed this proposition by briefly presenting the *C. difficile* life cycle and describing the toxins produced. We then described the current laboratory-based diagnostic tools for CDI patient screening. We discussed the potential use of miRNA to monitor and improve the management of CDI patients.

C. DIFFICILE LIFE CYCLE AND TOXINS

C. difficile is a Gram-positive, anaerobic bacterium belonging to the phylum Firmicutes. There are three main stages that define the *C. difficile* life cycle: spore formation; germination; and growth (vegetative). At the spore stage (dormant phase), it is typically harmless in a balanced gut flora microenvironment. *C. difficile* can resist oxygen, heat and many other environmental insults, including ethanol-based disinfectants (Figure 1)[18].

Once set in a stable environment, spores germinate rapidly and produce two major toxins, toxin A and toxin B encoded by *TcdA* and *TcdB*, which are located at the 19.6 kbp long pathogenicity locus region (Figure 2)[19]. Toxin A and toxin B trigger cytosol translocation of target host cells and inactivate small GTP-binding proteins (such as CDC42, Rho and Rac) through monoglucosylation, leading to actin condensation, cytoskeleton disintegration, cell rounding and apoptosis[20]. *tcdR* is an RNA polymerase sigma factor that initiates *tcdA* and *tcdB* translation *via* its two tandem promoters[21,22] and is involved in the final stages of flagellar assembly[23]. Some *C. difficile* strains, such as ribotype 027 and ribotype 078 are able to produce *C. difficile* transferase toxin, an actin-specific ADP-ribosyltransferase homologous to iota-toxin from *Clostridium perfringens* and *Clostridium spiroforme* toxin, and potentially enhances *C. difficile* virulence and disease severity[24,25].

CURRENT DIAGNOSTIC TOOLS FOR IDENTIFYING PATIENTS WITH C. DIFFICILE INFECTION

Similar to colorectal cancer screening, CDI can be detected by examining the colon through flexible sigmoidoscopy or colonoscopy to look for pseudomembranes and inflamed areas. X-ray abdominal imaging or computerised tomography scan can also be applied on a case-by-case basis. In addition to the invasive approaches, the cost effective, non-invasive faecal-based screening is the first-line approach for CDI diagnosis. Still, it varies widely due to different clinical microbiology methods and their different accuracy and variance[26,27]. These methods include cell cytotoxicity neutralisation assay, toxigenic culture (TC), enzyme immunoassay (EIAs) [including toxins and glutamate dehydrogenase (GDH)] and nucleic acid amplification test (NAAT) and each of the methods has advantages and disadvantages in terms of turn-around time and the screening performance (Table 1).

Cell cytotoxicity neutralisation assay and C. difficile culture

The cell cytotoxicity neutralisation assay is the first-line faecal-based diagnostic test for CDI[28,29]. It requires multiple steps in order to isolate *C. difficile* toxins from faeces and at least 24 h of cell culture (mainly human fibroblasts). The cytopathic effect is characterised by rounding and morphologic changes of the cultured cells[29,30], and the phenomena must also be reverted by *C. difficile* or *Clostridium sordellii* anti-toxin used as a control to prove that the cytopathic effect is not related to nonspecific substances in the faeces. In contrast, toxigenic culture requires faeces inoculation to selective cycloserine-cefoxitin-fructose, chromogenic or similar agar plates for a specific incubation period; suspicious colonies are selected for further bacteria culture and/or *C. difficile* toxin test to confirm the finding (Figure 3)[31-33]. It is important to remember that there is no standard to eliminate or reduce nonspecific bacteria colonisation from *C. difficile* culture. Heat shock and alcohol shock are the traditional preculture approaches, while a culture media containing bacteria “suppressors” such as antibiotics may also be applied[34-38]. Both culture-based assays are time-consuming, labour-intensive and require a certain level of laboratory skill. As such, it is unlikely to be used for first-line clinical screening and is commonly used as the reference method for research and outbreak investigations, even though it is considered the gold standard[31,32,38].

Nucleic acid-based detection assays

The nucleic acid amplification test is a quantitative real-time (qRT)-PCR-based diagnostic assay able to rapidly detect *C. difficile* toxin genes such as *tcdA*, *tcdB*, *tcdBv*, *cdt* and/or *tcdCA117* at the DNA level. There is a wide range of United States Food and Drug Administration-approved detection assays, from *C. difficile* specific point-of-care testing to high-volume, high-throughput multiple gastrointestinal pathogens laboratory tests. The majority of PCR detection approaches for *C. difficile* screening are probe-based qRT-PCR (Table 2). The use of probes increases amplification specificity during the PCR cycle since the additional sequence of the probe is specific for and binds to the *C. difficile* DNA sequence. Additionally, it is possible to perform multiplex qRT-PCR by using different fluorescent dyes[39]. The

Table 1 Summary of *Clostridioides difficile* diagnostic tests

| Test | Abbreviation | Sensitivity | Specificity | Turn-around time | Target substance |
|--|--------------|-------------|------------------|------------------|--|
| Culture-based | | | | | |
| Cell cytotoxicity neutralisation assay | CCTN | High | High | < 24 h | Toxins |
| Toxigenic culture | TC | High | Low ¹ | > 3 d | <i>C. difficile</i> vegetative cells or spores |
| DNA-based | | | | | |
| Nucleic acid amplification test ² | NAAT | High | Low/moderate | < 4 h | Toxin genes |
| Protein-based | | | | | |
| Glutamate dehydrogenase | GDH-EIA | High | Low ¹ | < 2 h | <i>C. difficile</i> antigens |
| Toxin A and B enzyme immunoassays | EIA | Low | Moderate | < 2 h | Toxins |

¹Nucleic acid amplification test, mainly using the PCR technique.

²Must be combined with a toxin test.

C. difficile: *Clostridioides difficile*; TC: Toxigenic culture; NAAT: Nucleic acid amplification test; CCTN: Cell cytotoxicity neutralisation assay; GDH: Glutamate dehydrogenase; EIA: Enzyme immunoassay.




Figure 1 *Clostridioides difficile* life cycle. *Clostridioides difficile* (*C. difficile*) can be found in soil and is transmitted to humans (as well as animals) through different daily activities. Besides hospital-acquired *C. difficile* infections, community-acquired *C. difficile* infections are also known, with agriculture being one of the main sources, from the spore stage into the human digestive system. Once stable, *C. difficile* may repopulate and release toxins that can affect intestinal health. *C. difficile* may go back to the environment and repeat the life cycle. GDH: Glutamate dehydrogenase.

nucleic acid-based *C. difficile* toxin screening has over ten times higher sensitivity than a cytotoxin assay [40,41], but the screening specificity is relatively low due to high false positive cases from asymptomatic infection. As a result, optimisation is required, especially on PCR threshold cycle settings [42,43]. In addition, patient preselection based on clinical symptoms and intestinal inflammation biomarkers (*i.e.* faecal calprotectin, lactoferrin and cytokines) appears to be necessary to reduce the risk of a false positive [27,43-47].

Toxins and GDH EIA


EIAs utilise antibodies to detect the presence of antigens. It is still relatively common to detect toxin A, toxin B and/or GDH in faeces for CDI. There are several types of EIAs available for CDI, including microplates (enzyme-linked immunosorbent assay), membrane EIA, chemiluminescence immunoassay, enzyme-linked fluorescent assay and chromatographic immunoassay (Table 3). A meta-analysis

Table 2 Selected Food and Drug Administration-approved molecular assays

| Assay name | Developer | Target | Method | Sensitivity/specificity (%) |
|---|---------------------------------|--|---|-----------------------------|
| AmpliVue <i>C. difficile</i> assay[70] | Quidel | <i>tcdA</i> | Isothermal nucleic acid amplification | 93.6/94.1 |
| ARIES <i>C. difficile</i> assay[71,72] | Luminex | <i>tcdA</i> and <i>tcdB</i> | qRT-PCR | 90-98/92-98 |
| ARTUS <i>C. difficile</i> QS-RGQ MDX Kit [73] | QIAGEN, GMBH | <i>tcdA</i> and <i>tcdB</i> (+ <i>tcdBv</i>) | qRT-PCR | 100/90-100 |
| BD Diagnostics BD MAX <i>C. diff</i> assay[71,74-77] | GeneOhm Sciences | <i>tcdB</i> | TaqMan probe-based qRT-PCR | 86-98/89-100 |
| BD GeneOhm <i>C. diff</i> assay[78-82] | BD Diagnostics/GeneOhm Sciences | <i>tcdB</i> | Beacon probe-based PCR | 91-95/96-100 |
| Cobas <i>C. diff</i> Nucleic Acid Test For Use On The Cobas Liat System[83, 84] | Roche | <i>tcdB</i> | TaqMan probe-based qRT-PCR | 93/99 |
| GenePOC <i>C. diff</i> [85] | GenePOC | <i>tcdB</i> of toxigenic <i>C</i> | TaqMan probe-based qRT-PCR | 81/97 |
| ICEplex <i>C. diff</i> Kit ¹ [86] | PrimeraDx | <i>tcdB</i> | qRT-PCR + capillary electrophoresis-based detection | 90/97 |
| Illumigene <i>C. diff</i> DNA Amplification assay[77] | Meridian Bioscience | <i>tcdA</i> | Loop-mediated isothermal DNA amplification | 82-100/94-100 |
| IMDx <i>C. difficile</i> for Abbott m2000 [76,77] | Intelligent Medical Devices | <i>tcdA</i> and <i>tcdB</i> (+ <i>tcdBv</i>) | Probe-based qRT-PCR | 62-84/94-99 |
| Portrait Toxigenic <i>C. difficile</i> assay [87,88] | Great Basin Scientific | <i>tcdB</i> | Primer-mediated helicase-dependent amplification + chip-based detection | 98.2/92.8 |
| ProGastro Cd assay[81,89] | Prodesse | <i>tcdB</i> | Probe-based qRT-PCR | 77-100/94-99 |
| Quidel Molecular Direct <i>C. difficile</i> assay[70,90] | Quidel | <i>tcdA</i> and <i>tcdB</i> | TaqMan probe-based qRT-PCR | 82-96/97-100 |
| Simplexa <i>C. difficile</i> Universal Direct assay[70,91] | Focus Diagnostics | <i>tcdB</i> | qRT-PCR + bifunctional fluorescent primer-probes | 87-98/99-100 |
| Solana <i>C. difficile</i> assay ¹ [92] | Quidel | <i>tcdA</i> | Helicase-dependent amplification | 93/99 |
| Verigene <i>C. difficile</i> Nucleic acid Test [91,93,94] | Nanosphere | <i>tcdA</i> , <i>tcdB</i> , <i>cdt</i> and <i>tcdCA117</i> | PCR + nanoparticle-based array | 94-96/96-98 |
| X/Pert <i>C. difficile</i> /Epi[71,77,95,96] | Cepheid | <i>tcdA</i> , <i>tcdB</i> , <i>cdt</i> and <i>tcdCA117</i> | TaqMan probe-based qRT-PCR | 90-100/93-99 |

¹The sensitivity and specificity were provided by the manufacturer.

tcdCA117: The *tcdC* deletion nt 117; *tcdBv*: *tcdB* variant; *cdt*: Binary toxin; *C. difficile* or *C. diff*: *Clostridioides difficile*; qRT: Quantitative real-time.



DOI: 10.3748/wjg.v29.i22.3385 Copyright ©The Author(s) 2023.

Figure 2 Pathogenicity loci of toxigenic *Clostridioides difficile*. The 19.6 kbp long pathogenicity loci in toxigenic *Clostridioides difficile*, including *tcdC*, *tcdA*, *tcdE*, *tcdB* and *tcdR* coding genes. *tcdR* codes for an RNA polymerase sigma factor that controls the expression of the *tcdB* and *tcdA* genes and possibly *tcdE*. The transcription of *tcdR* can be regulated by three promoters. One is under the control of σ^D , and the other two are autoregulatory tandem promoters. Figure adopted and modified from Isidro *et al*[19].

published in 2016 evaluated the major commercially available *C. difficile* diagnosis assays compared to the gold standards. The pooled sensitivities were 83% [95% confidence interval (CI): 76%-88%] and 57% (95%CI: 51%-63%) compared to cell culture cytotoxicity assay and toxigenic bacterial culture,

Table 3 Major immunochromatographic membrane assays

| Methods/assays | Target(s) | Developer | Cell cytotoxicity assay | | Toxicogenic culture | |
|--|-------------|---------------------------------|-------------------------|-----------|---------------------|-----------|
| | | | Sen, % | Spe, % | Sen, % | Spe, % |
| Microwell enzyme immunoassay (enzyme-linked immunosorbent assay) | | | | | | |
| GA <i>C. diff</i> Antigen[97] | Toxin A + B | The Binding Site | 76.8 | 90.0 | 68.8 | 91.4 |
| Premier toxin A+B[97-106] | Toxin A + B | Meridian Bioscience | 58-99 | 94-100 | 40-86 | 91-100 |
| Ridascreen toxin A/B[97,107,108] | Toxin A + B | Ridascreen | 57-67 | 95-97 | 52-60 | 96-98 |
| ProSpecT toxin A/B[97,109] | Toxin A + B | Remel/Oxoid (Thermo Scientific) | 90-91 | 93-97 | 82 | 93 |
| Techlab <i>C. diff</i> Chek-60 (GDH)[53,97,110] | GDH | Techlab | 92.0-93.5 | 94.0-98.0 | 88.0-93.0 | 94.0-97.0 |
| TechLab toxin A/B II[81,97,100,109-111] | Toxin A + B | TechLab | 72-91 | 87-100 | 58-85 | 96-99 |
| Membrane enzyme immunoassay | | | | | | |
| ImmunoCard toxins A/B[41,97,109,112,113] | Toxin A + B | Meridian Bioscience | 85-96 | 97-99 | 41-69 | 93-99 |
| Quick Chek Complete[40,105,112,114-117] | Toxin A + B | TechLab | 50-73 | 100 | 29-79 | 89-100 |
| Remel X/pect <i>C. diff</i> toxin A/B[97,113,118] | Toxin A + B | Remel | 44-83 | 99-100 | 48-69 | 95-99 |
| Tox A/B Quick Check[97,115,119-121] | Toxin A + B | TechLab | 61-84 | 99 | 40-74 | 94-100 |
| Chemiluminescence immunoassay | | | | | | |
| Liaison <i>C. difficile</i> toxins A and B[122,123] | Toxin A + B | DiaSorin | 88 | 95 | 69-88 | 95-99 |
| Enzyme-linked fluorescent assay | | | | | | |
| Vidas toxin A and B[97,116,123-128] | Toxin A + B | Vidas | 53-98 | 99-100 | 44-80 | 95-99 |
| Vidas GDH[40,129] | GDH | Vidas | 97 | 87 | 56 | 100 |

Sen: Sensitivity; Sep: Specificity; GDH: Glutamate dehydrogenase; *C. difficile* or *C. diff*: *Clostridioides difficile*.




Figure 3 Idealised summary of toxigenic culture and cell cytotoxicity neutralisation assay for *Clostridioides difficile* infection identification. In toxigenic culture, the faecal sample is first exposed to heat shock or alcohol shock to kill *Clostridioides difficile* (*C. difficile*) and other microorganisms, and heat/alcohol resistant spores of *C. difficile* survive. The sample is then plated on selective agar and incubated anaerobically at 37 °C for at least 48 h to observe and confirm the colonisation of *C. difficile*. For the cell cytotoxicity neutralisation assay, the faecal sample is filtered and added to a toxin-sensitive cell line with/without antiserum. After 24-48 h of incubation, the cytopathological effect is then examined microscopically.

respectively, at a specificity of 99%[48]. This may be because these EIAs were developed in the early 21st century and are less sensitive to low toxin(s) levels, and immunocompromised CDI patients have a lower concentration trigger point[49]. This meta-analysis also indicated that GDH detection had a range

of 94% (95% CI: 86%-97%) for sensitivity and 96% (95% CI: 92%-98%) for specificity compared to toxigenic bacterial culture and cell culture cytotoxicity assay together[48]. However, a few studies reported sensitivities below 90% for GDH assays[38,50,51]. Due to the known limitations and relatively poor accuracy, stand-alone toxin or GDH EIA tests are not recommended by professional medical societies, including the European Society of Clinical Microbiology and Infectious Diseases and the Infectious Diseases Society of America[27,48,52].

As a result, several multiple-step diagnostic algorithms have been proposed to improve assay performance and detection accuracy. For example, a two-step algorithm initially detects GDH, and positive GDH cases are followed up with a toxin A and/or toxin B immunoassay. If the toxin immunoassay result is negative, a bacterial culture will be performed[53]. In addition, new protein-based assays such as lateral flow assay are under development and may potentially yield a result in 15 min[54].

MIRNA DYSREGULATION AND *C. DIFFICILE* INFECTION DETECTION AND MONITORING POTENTIAL

miRNAs are small single-stranded endogenous RNA molecules that are key regulators of gene expression and silencing at the post-transcriptional level. miRNA complex biosynthesis begins in the nucleus where primary miRNAs are produced by transcription of miRNAs from DNA sequences or miRNA genes. Precursor miRNAs are transcripts of approximately 60-110 nucleotides in length with a shorter stem-loop structure, produced from primary miRNAs by RNase type III enzymes (DROSHA) and undergo several maturation processes inside and outside the nucleus to form mature miRNAs, which are transported into the cytoplasm[55].

The stability of miRNA-specific target mRNAs is disturbed when RNA-induced silencing complexes possess loaded miRNAs. A portion of the miRNA, the seed sequence, which is two to eight nucleotides long, pairs with a specific sequence on the target mRNA and is referred to as an miRNA response element that results in translational repression and degradation of the target mRNA due to the binding of miRNAs in the 3' untranslated region. miRNAs primarily repress genes by inhibiting protein synthesis, preventing elongation and ribosome decline and disrupting mRNAs through the processes of demethylation and decap, resulting in their degradation[56].

miRNAs have the potential to act *via* molecular mechanisms at every step of CDI, inhibiting specific transcripts or inflammatory molecule transcription, thereby influencing the pathology grade. The imbalance of these biomarkers can be measured and exploited for diagnosis, coupled with standard methods to strengthen the results. In particular, miRNAs are easily detectable (through sequencing, RT-qPCR, *etc*) in body fluids such as saliva, blood and even faecal material, and their levels correlate with target transcript alterations or non-physiological events[57]. These biomarkers are contributing increasingly to the establishment of less invasive "liquid biopsies," which is important and appealing for patient compliance compared to normal, invasive biopsies that require a long time for results. Although, it cannot fully substitute canonical diagnosis methods in most cases currently, it will undoubtedly happen in the near future.

Numerous studies have shown that miRNAs can be used to detect diseases and for their management. This may apply to patients with CDI. However, studies of the relationship between CDI and host miRNA are limited. To the best of our knowledge, the first reported study utilised C57BL/6J wild-type mice with a CDI model and identified the induction of mmu-miR-146b, mmu-miR-1940 and mmu-miR-1298 expression and upregulated proinflammatory cytokine expression, such as monocyte chemoattractant protein-1, interleukin (IL)-6, IL-17 and IL-1 β in colonic tissues[58]. The authors also showed that the miR-146b potentially targets nuclear receptor co-activator 4 (NCOA4), *CD36* and *GLUT4* mRNA expression levels were downregulated. *In silico* simulation predicts upregulation of mmu-miR-146b and IL-17 resulting in the downregulation of *NCOA4* and peroxisome proliferator-activated receptor gamma (*PPAR- γ*) in the CDI mice model. Null mice silenced for *PPAR- γ* in T cells following CDI presented more severe colonic disease activity, inflammatory lesions and inflammatory cytokine expression[58]. There is also a filed patent claiming that miR-27a-5p could modulate the inflammatory response induced by CDI[59]. The inventors claim that miR-27a-5p can be linked to a matrix and delivered by vectors and/or incorporated into particles. The miR-27a-5p-linked particle could be administered to infected subjects for the treatment[59]. In faeces, a small-scale study with only 8 CDI participants demonstrated that a higher level of faecal hsa-miR-1246 was found in human CDI patients compared to the control group[60].

FMT has been proven in the treatment of recurrent CDI[61,62]. It is intended to restore colonic microbiota through introducing "healthy" bacteria *via* colonoscopy, enema or oral capsules that contain bacteria in a powder form. However, the safety concerns of FMT could be an obstacle to extending the application as a regular treatment strategy[63,64]. To monitor treatment conditions, detecting a panel of miRNA markers in circulation could help physicians make a more accurate decision[65,66]. Another study showed that 71 different circulating miRNAs were found to be expressed in 126 sera from 42 patients at 4 wk and 12 wk after FMT treatment[65]. The authors used qRT-PCR and 3' untranslated




Figure 4 *Clostridioides difficile* and microRNAs cross-interact inside the cells. microRNA (miRNA) is a small single-stranded RNA that plays a key role in gene expression regulation. It starts in the cell nucleus, where primary miRNAs are produced by RNA Pol II through miRNA transcription from DNA sequences or miRNA genes. Precursor miRNA, around 60-110 nucleotides long transcripts with a shorter stem-loop structure, are produced from primary miRNAs by RNase type III (DROSHA) enzyme with several maturation processes and is then transported to the cytoplasm *via* DICER. Toxin B from *Clostridioides difficile* may interfere with DROSHA function. A fraction of miRNA binding specific sequences (2-8 nucleotides long) can pair with miRNA response elements in the 3' untranslated region of the target mRNA, causing translational repression and degradation of the target mRNA. Thus, miRNA expression patterns can indicate non-physiological events such as *Clostridioides difficile* infection. By detecting changes in miRNA patterns in body fluids, such as saliva, blood, and stool, the screening accuracy can be improved. miRNA: microRNA; pri-miRNA: Primary miRNA; pre-miRNA: Precursor miRNA; *C. difficile*: *Clostridioides difficile*.

region luciferase reporter assays to validate the top miRNA candidates and confirmed that hsa-miR-23a-3p, hsa-miR-150-5p, hsa-miR-26b-5p and hsa-miR-28-5p expression levels inversely correlated with the sera protein and cell-free circulating mRNA on several inflammation-related biomarkers, such as IL-12B, IL-18, FGF21 and TNFRSF9[65].

In a mouse model of relapsing CDI, qRT-PCR analyses of faecal and sera RNA extracts revealed inhibition of these miRNAs, while the FMT treatment enabled the recovery of their inhibitory effect. This study also showed that toxin B (TcdB) mediates the inhibitory effect of CDI on miRNA *via* DROSHA, based on the human colonoids and the mice colon models, where miR-23a and miR-150 were used to demonstrate the cytoprotective effects against TcdB[65]. A small, in-depth phenomics study of four adults treated with sequential FMT for severe or fulminant CDI found that miR-451a and miR-16 from the serum samples were upregulated in the responders *vs* the non-responders on average across all timepoints[66].

Using miRNAs as a diagnostic tool for CDI presents both opportunities and challenges. On one hand, as miRNAs play a role in controlling and influencing gene expression, changes in their activity and expression levels can be associated with different pathological events. This makes miRNA expression patterns a potentially powerful diagnostic tool, with the potential for use in therapeutic applications. Monitoring the response to FMT with miRNA can be an additional indicator for personalised treatment, and miRNA detection from non-invasive sources, such as blood, faeces, urine and saliva, can provide convenient and longitudinal measurements of miRNA levels for CDI. On the other hand, the fact that miRNA can be derived from blood cells released by different pathological events makes detecting CDI specifically a challenging task. Therefore, the use of miRNAs as a diagnostic tool for CDI requires further research and validation. Figure 4 provides a schematic summary of the intracellular mechanisms discussed and the potential use of miRNA profiling from a variety of body fluids, such as liquid biopsies, for diagnostic purposes as demonstrated in various research studies related to colorectal cancer screening[67-69].

CONCLUSION

To date, current laboratory-based CDI assays have varied in their detection accuracy. The expression of miRNAs has become increasingly important as novel biomarkers for assessment. The different signature profiles obtained through the differential expression of these small non-coding RNAs are essential for

early diagnosis and prediction of therapeutic response and disease management, these are also including cancer and infection. Notably, this can be accomplished by using liquid biopsy, enabling a non-invasive and low-cost screening approach. This approach may also be used to detect *C. difficile* infections, while further research and validation are clearly needed. These reported miRNA studies can be used in conjunction with current diagnostic tools to improve diagnostic accuracy aiding in patient management for both symptomatic and asymptomatic CDI patients.

FOOTNOTES

Author contributions: Yau TO and Bocchetti M contributed to conceptualisation; Yau TO, Bocchetti M and Ferraro MG wrote the original draft; Yau TO, Bocchetti M, Ferraro MG, Melisi F, Grisolia P, Scrima M and Cossu AM wrote the review and contributed to editing; Yau TO and Bocchetti M contributed to visualisation; Yau TO performed the project administration and funding acquisition; All authors read and agreed to the published version of the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: United Kingdom

ORCID number: Marco Bocchetti 0000-0002-2143-6669; Tung On Yau 0000-0002-3283-0370.

S-Editor: Fan JR

L-Editor: Filipodia

P-Editor: Yu HG

REFERENCES

1. U. S. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Atlanta, Georgia. Available from: <https://stacks.cdc.gov/view/cdc/82532>
2. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. *N Engl J Med* 2015; **372**: 825-834 [PMID: 25714160 DOI: 10.1056/NEJMoa1408913]
3. Karlsson S, Dupuy B, Mukherjee K, Norin E, Burman LG, Akerlund T. Expression of Clostridium difficile toxins A and B and their sigma factor TcdD is controlled by temperature. *Infect Immun* 2003; **71**: 1784-1793 [PMID: 12654792 DOI: 10.1128/iai.71.4.1784-1793.2003]
4. Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. *Curr Opin Crit Care* 2007; **13**: 450-455 [PMID: 17599017 DOI: 10.1097/MCC.0b013e3282638879]
5. Yau TO, Vadakekolathu J, Foulds GA, Du G, Dickens B, Polytarchou C, Rutella S. Hyperactive neutrophil chemotaxis contributes to anti-tumor necrosis factor- α treatment resistance in inflammatory bowel disease. *J Gastroenterol Hepatol* 2022; **37**: 531-541 [PMID: 34931384 DOI: 10.1111/jgh.15764]
6. Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. *Therap Adv Gastroenterol* 2021; **14**: 17562848211016248 [PMID: 34093740 DOI: 10.1177/17562848211016248]
7. Kachrimanidou M, Tzika E, Filioussis G. Clostridioides (Clostridium) Difficile in Food-Producing Animals, Horses and Household Pets: A Comprehensive Review. *Microorganisms* 2019; **7** [PMID: 31835413 DOI: 10.3390/microorganisms7120667]
8. Muñoz-Price LS, Hanson R, Singh S, Nattinger AB, Penlesky A, Buchan BW, Ledeboer NA, Beyer K, Namin S, Zhou Y, Pezzin LE. Association Between Environmental Factors and Toxigenic Clostridioides difficile Carriage at Hospital Admission. *JAMA Netw Open* 2020; **3**: e1919132 [PMID: 31922563 DOI: 10.1001/jamanetworkopen.2019.19132]
9. Monaghan TM, Biswas RN, Nashine RR, Joshi SS, Mullish BH, Seekatz AM, Blanco JM, McDonald JAK, Marchesi JR, Yau TO, Christodoulou N, Hatziaepostolou M, Pucic-Bakovic M, Vuckovic F, Klicek F, Lauc G, Xue N, Dottorini T, Ambalkar S, Satav A, Polytarchou C, Acharjee A, Kashyap RS. Multiomics Profiling Reveals Signatures of Dysmetabolism in Urban Populations in Central India. *Microorganisms* 2021; **9** [PMID: 34361920 DOI: 10.3390/microorganisms9071485]
10. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. *Am J Gastroenterol* 2012; **107**: 1001-1010 [PMID: 22710578 DOI: 10.1038/ajg.2012.179]
11. Roughhead EE, Chan EW, Choi NK, Griffiths J, Jin XM, Lee J, Kimura M, Kimura T, Kubota K, Lai EC, Man KK, Nguyen TA, Ooba N, Park BJ, Sato T, Shin JY, Wang T, Wong IC, Yang YK, Pratt NL. Proton pump inhibitors and risk of Clostridium difficile infection: a multi-country study using sequence symmetry analysis. *Expert Opin Drug Saf* 2016;

- 15: 1589-1595 [PMID: [27645304](#) DOI: [10.1080/14740338.2016.1238071](#)]
- 12 **Rineh A**, Kelso MJ, Vatansever F, Tegos GP, Hamblin MR. Clostridium difficile infection: molecular pathogenesis and novel therapeutics. *Expert Rev Anti Infect Ther* 2014; **12**: 131-150 [PMID: [24410618](#) DOI: [10.1586/14787210.2014.866515](#)]
- 13 **Lyras D**, Adams V, Lucet I, Rood JI. The large resolvase TnpX is the only transposon-encoded protein required for transposition of the Tn4451/3 family of integrative mobilizable elements. *Mol Microbiol* 2004; **51**: 1787-1800 [PMID: [15009902](#) DOI: [10.1111/j.1365-2958.2003.03950.x](#)]
- 14 **Sebaihia M**, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeño-Tárraga AM, Wang H, Holden MT, Wright A, Churcher C, Quail MA, Baker S, Bason N, Brooks K, Chillingworth T, Cronin A, Davis P, Dowd L, Fraser A, Feltwell T, Hance Z, Holroyd S, Jagels K, Moule S, Mungall K, Price C, Rabinowitsch E, Sharp S, Simmonds M, Stevens K, Unwin L, Whithead S, Dupuy B, Dougan G, Barrell B, Parkhill J. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. *Nat Genet* 2006; **38**: 779-786 [PMID: [16804543](#) DOI: [10.1038/ng1830](#)]
- 15 **Maxwell-Scott HG**, Goldenberg SD. Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents. *Med Mal Infect* 2018; **48**: 1-9 [PMID: [29169816](#) DOI: [10.1016/j.medmal.2017.10.008](#)]
- 16 **Hensgens MP**, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. *J Antimicrob Chemother* 2012; **67**: 742-748 [PMID: [22146873](#) DOI: [10.1093/jac/dkr508](#)]
- 17 **Bagdasarjan N**, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. *JAMA* 2015; **313**: 398-408 [PMID: [25626036](#) DOI: [10.1001/jama.2014.17103](#)]
- 18 **Wilcox MH**. Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis. *Best Pract Res Clin Gastroenterol* 2003; **17**: 475-493 [PMID: [12763508](#) DOI: [10.1016/s1521-6918\(03\)00017-9](#)]
- 19 **Isidro J**, Mendes AL, Serrano M, Henriques AO, Oleastro M. Overview of Clostridium difficile Infection: Life Cycle, Epidemiology, Antimicrobial Resistance and Treatment. In: Clostridium Difficile-A Comprehensive Overview. *InTech* 2017 [DOI: [10.5772/intechopen.69053](#)]
- 20 **Voth DE**, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. *Clin Microbiol Rev* 2005; **18**: 247-263 [PMID: [15831824](#) DOI: [10.1128/CMR.18.2.247-263.2005](#)]
- 21 **Mani N**, Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. *Proc Natl Acad Sci U S A* 2001; **98**: 5844-5849 [PMID: [11320220](#) DOI: [10.1073/pnas.101126598](#)]
- 22 **Mani N**, Lyras D, Barroso L, Howarth P, Wilkins T, Rood JI, Sonenshein AL, Dupuy B. Environmental response and autoregulation of Clostridium difficile TxeR, a sigma factor for toxin gene expression. *J Bacteriol* 2002; **184**: 5971-5978 [PMID: [12374831](#) DOI: [10.1128/jb.184.21.5971-5978.2002](#)]
- 23 **El Meouche I**, Peltier J, Monot M, Soutourina O, Pestel-Caron M, Dupuy B, Pons JL. Characterization of the SigD regulon of C. difficile and its positive control of toxin production through the regulation of tcdR. *PloS One* 2013; **8**: e83748 [PMID: [24358307](#) DOI: [10.1371/journal.pone.0083748](#)]
- 24 **Perelle S**, Gibert M, Bourlioux P, Corthier G, Popoff MR. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. *Infect Immun* 1997; **65**: 1402-1407 [PMID: [9119480](#) DOI: [10.1128/IAI.65.4.1402-1407.1997](#)]
- 25 **Barth H**, Aktories K, Popoff MR, Stiles BG. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. *Microbiol Mol Biol Rev* 2004; **68**: 373-402, table of contents [PMID: [15353562](#) DOI: [10.1128/MMBR.68.3.373-402.2004](#)]
- 26 **Lübbert C**, John E, von Müller L. Clostridium difficile infection: guideline-based diagnosis and treatment. *Dtsch Arztebl Int* 2014; **111**: 723-731 [PMID: [25404529](#) DOI: [10.3238/arztebl.2014.0723](#)]
- 27 **McDonald LC**, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018; **66**: e1-e48 [PMID: [29462280](#) DOI: [10.1093/cid/cix1085](#)]
- 28 **Bartlett JG**, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. *N Engl J Med* 1978; **298**: 531-534 [PMID: [625309](#) DOI: [10.1056/NEJM197803092981003](#)]
- 29 **Chang TW**, Lauermaun M, Bartlett JG. Cytotoxicity assay in antibiotic-associated colitis. *J Infect Dis* 1979; **140**: 765-770 [PMID: [231071](#) DOI: [10.1093/infdis/140.5.765](#)]
- 30 **Tichota-Lee J**, Jaqua-Stewart MJ, Benfield D, Simmons JL, Jaqua RA. Effect of age on the sensitivity of cell cultures to Clostridium difficile toxin. *Diagn Microbiol Infect Dis* 1987; **8**: 203-214 [PMID: [3449315](#) DOI: [10.1016/0732-8893\(87\)90051-4](#)]
- 31 **Perry JD**. A Decade of Development of Chromogenic Culture Media for Clinical Microbiology in an Era of Molecular Diagnostics. *Clin Microbiol Rev* 2017; **30**: 449-479 [PMID: [28122803](#) DOI: [10.1128/CMR.00097-16](#)]
- 32 **Housman ST**, Banevicius MA, Lamb LM, Nicolau DP. Isolation and quantitation of Clostridium difficile in aqueous and fecal matter using two types of selective media. *J Microbiol Immunol Infect* 2016; **49**: 445-447 [PMID: [26198865](#) DOI: [10.1016/j.jmii.2015.05.012](#)]
- 33 **Binning M**, John MA, Schieven BC, Austin TW, Lannigan R, Hussain Z. Comparison of culture, cytotoxin assay and two EIA tests with clinical diagnosis of Clostridium difficile-associated diarrhea. *Can J Infect Dis* 1994; **5**: 163-167 [PMID: [22346495](#) DOI: [10.1155/1994/804205](#)]
- 34 **Tyrrell KL**, Citron DM, Leoncio ES, Merriam CV, Goldstein EJ. Evaluation of cycloserine-cefoxitin fructose agar (CCFA), CCFA with horse blood and taurocholate, and cycloserine-cefoxitin mannitol broth with taurocholate and lysozyme for recovery of Clostridium difficile isolates from fecal samples. *J Clin Microbiol* 2013; **51**: 3094-3096 [PMID: [23804392](#) DOI: [10.1128/JCM.00879-13](#)]
- 35 **Hink T**, Burnham CA, Dubberke ER. A systematic evaluation of methods to optimize culture-based recovery of Clostridium difficile from stool specimens. *Anaerobe* 2013; **19**: 39-43 [PMID: [23247066](#) DOI: [10.1016/j.anaerobe.2012.12.001](#)]

- 36 **Mundy LS**, Shanholtzer CJ, Willard KE, Gerding DN, Peterson LR. Laboratory detection of *Clostridium difficile*. A comparison of media and incubation systems. *Am J Clin Pathol* 1995; **103**: 52-56 [PMID: [7817945](#) DOI: [10.1093/ajcp/103.1.52](#)]
- 37 **Bliss DZ**, Johnson S, Clabots CR, Savik K, Gerding DN. Comparison of cycloserine-cefoxitin-fructose agar (CCFA) and taurocholate-CCFA for recovery of *Clostridium difficile* during surveillance of hospitalized patients. *Diagn Microbiol Infect Dis* 1997; **29**: 1-4 [PMID: [9350408](#) DOI: [10.1016/s0732-8893\(97\)00113-2](#)]
- 38 **Burnham CA**, Carroll KC. Diagnosis of *Clostridium difficile* infection: an ongoing conundrum for clinicians and for clinical laboratories. *Clin Microbiol Rev* 2013; **26**: 604-630 [PMID: [23824374](#) DOI: [10.1128/CMR.00016-13](#)]
- 39 **Angione SL**, Sarma AA, Novikov A, Seward L, Fieber JH, Mermel LA, Tripathi A. A novel subtyping assay for detection of *Clostridium difficile* virulence genes. *J Mol Diagn* 2014; **16**: 244-252 [PMID: [24434086](#) DOI: [10.1016/j.jmoldx.2013.11.006](#)]
- 40 **Xiao Y**, Liu Y, Qin X. Comparative Study of *Clostridium difficile* Clinical Detection Methods in Patients with Diarrhoea. *Can J Infect Dis Med Microbiol* 2020; **2020**: 8753284 [PMID: [32064010](#) DOI: [10.1155/2020/8753284](#)]
- 41 **van den Berg RJ**, Bruijnesteijn van Coppenraet LS, Gerritsen HJ, Endtz HP, van der Vorm ER, Kuijper EJ. Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of *Clostridium difficile*-associated diarrhea in hospitalized patients. *J Clin Microbiol* 2005; **43**: 5338-5340 [PMID: [16208012](#) DOI: [10.1128/JCM.43.10.5338-5340.2005](#)]
- 42 **Crobach MJT**, Duszenko N, Terveer EM, Verduin CM, Kuijper EJ. Nucleic Acid Amplification Test Quantitation as Predictor of Toxin Presence in *Clostridium difficile* Infection. *J Clin Microbiol* 2018; **56** [PMID: [29237788](#) DOI: [10.1128/JCM.01316-17](#)]
- 43 **Anikst VE**, Gaur RL, Schroeder LF, Banaei N. Organism burden, toxin concentration, and lactoferrin concentration do not distinguish between clinically significant and nonsignificant diarrhea in patients with *Clostridium difficile*. *Diagn Microbiol Infect Dis* 2016; **84**: 343-346 [PMID: [26778484](#) DOI: [10.1016/j.diagmicrobio.2015.11.022](#)]
- 44 **Dubberke ER**, Han Z, Bobo L, Hink T, Lawrence B, Copper S, Hoppe-Bauer J, Burnham CA, Dunne WM Jr. Impact of clinical symptoms on interpretation of diagnostic assays for *Clostridium difficile* infections. *J Clin Microbiol* 2011; **49**: 2887-2893 [PMID: [21697328](#) DOI: [10.1128/JCM.00891-11](#)]
- 45 **Buckel WR**, Avdic E, Carroll KC, Gunaseelan V, Hadhazy E, Cosgrove SE. Gut check: *Clostridium difficile* testing and treatment in the molecular testing era. *Infect Control Hosp Epidemiol* 2015; **36**: 217-221 [PMID: [25633006](#) DOI: [10.1017/ice.2014.19](#)]
- 46 **Popiel KY**, Gheorghe R, Eastmond J, Miller MA. Usefulness of Adjunctive Fecal Calprotectin and Serum Procalcitonin in Individuals Positive for *Clostridium difficile* Toxin Gene by PCR Assay. *J Clin Microbiol* 2015; **53**: 3667-3669 [PMID: [26354814](#) DOI: [10.1128/JCM.02230-15](#)]
- 47 **Crobach MJT**, Baktash A, Duszenko N, Kuijper EJ. Diagnostic Guidance for *C. difficile* Infections. *Adv Exp Med Biol* 2018; **1050**: 27-44 [PMID: [29383662](#) DOI: [10.1007/978-3-319-72799-8_3](#)]
- 48 **Crobach MJ**, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for *Clostridium difficile* infection. *Clin Microbiol Infect* 2016; **22** Suppl 4: S63-S81 [PMID: [27460910](#) DOI: [10.1016/j.cmi.2016.03.010](#)]
- 49 **Erb S**, Frei R, Strandén AM, Dangel M, Tschudin-Sutter S, Widmer AF. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of *Clostridium difficile* infection in immunocompromised patients. *Clin Microbiol Infect* 2015; **21**: 998.e9-998.e15 [PMID: [26232535](#) DOI: [10.1016/j.cmi.2015.07.016](#)]
- 50 **Terveer EM**, Crobach MJ, Sanders IM, Vos MC, Verduin CM, Kuijper EJ. Detection of *Clostridium difficile* in Feces of Asymptomatic Patients Admitted to the Hospital. *J Clin Microbiol* 2017; **55**: 403-411 [PMID: [27852676](#) DOI: [10.1128/JCM.01858-16](#)]
- 51 **Walkty A**, Lagacé-Wiens PR, Manickam K, Adam H, Pieroni P, Hoban D, Karlowsky JA, Alfa M. Evaluation of an algorithmic approach in comparison with the Illumigene assay for laboratory diagnosis of *Clostridium difficile* infection. *J Clin Microbiol* 2013; **51**: 1152-1157 [PMID: [23363829](#) DOI: [10.1128/JCM.03203-12](#)]
- 52 **Bouza E**, Aguado JM, Alcalá L, Almirante B, Alonso-Fernández P, Borges M, Cobo J, Guardiola J, Horcajada JP, Maseda E, Mensa J, Merchante N, Muñoz P, Pérez Sáenz JL, Pujol M, Reigadas E, Salavert M, Barberán J. Recommendations for the diagnosis and treatment of *Clostridioides difficile* infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR). *Rev Esp Quimioter* 2020; **33**: 151-175 [PMID: [32080996](#) DOI: [10.37201/req/2065.2020](#)]
- 53 **Fenner L**, Widmer AF, Goy G, Rudin S, Frei R. Rapid and reliable diagnostic algorithm for detection of *Clostridium difficile*. *J Clin Microbiol* 2008; **46**: 328-330 [PMID: [18032627](#) DOI: [10.1128/JCM.01503-07](#)]
- 54 **Qi H**, Sun Q, Ma Y, Wu P, Wang J. Advantages of Lateral Flow Assays Based on Fluorescent Submicrospheres and Quantum Dots for *Clostridium difficile* Toxin B Detection. *Toxins (Basel)* 2020; **12** [PMID: [33227925](#) DOI: [10.3390/toxins12110722](#)]
- 55 **Han J**, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev* 2004; **18**: 3016-3027 [PMID: [15574589](#) DOI: [10.1101/gad.1262504](#)]
- 56 **Jonas S**, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. *Nat Rev Genet* 2015; **16**: 421-433 [PMID: [26077373](#) DOI: [10.1038/nrg3965](#)]
- 57 **Cossu AM**, Scrima M, Lombardi A, Grimaldi A, Russo M, Ottaiano A, Caraglia M, Bocchetti M. Future directions and management of liquid biopsy in non-small cell lung cancer. *Explor Target Antitumor Ther* 2020; **1**: 239-252 [PMID: [36046776](#) DOI: [10.37349/etat.2020.00015](#)]
- 58 **Viladomiu M**, Hontecillas R, Pedragosa M, Carbo A, Hoops S, Michalak P, Michalak K, Guerrant RL, Roche JK, Warren CA, Bassaganya-Riera J. Modeling the role of peroxisome proliferator-activated receptor γ and microRNA-146 in mucosal immune responses to *Clostridium difficile*. *PLoS One* 2012; **7**: e47525 [PMID: [23071818](#) DOI: [10.1371/journal.pone.0047525](#)]
- 59 **Imad K**, Hussein K, Cécile L, Jean-christophe M. Use of the mir-27a-5p microRNA for treating *Clostridium difficile*-

- induced bowel inflammation. France patent EP3876948A1. September 15, 2021
- 60 **Verdier J**, Breunig IR, Ohse MC, Roubrocks S, Kleinfeld S, Roy S, Streetz K, Trautwein C, Roderburg C, Sellge G. Faecal Micro-RNAs in Inflammatory Bowel Diseases. *J Crohns Colitis* 2020; **14**: 110-117 [PMID: [31209454](#) DOI: [10.1093/ecco-jcc/jjz120](#)]
- 61 **Drekonja D**, Reich J, Gezahegn S, Greer N, Shaukat A, MacDonald R, Rutks I, Wilt TJ. Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review. *Ann Intern Med* 2015; **162**: 630-638 [PMID: [25938992](#) DOI: [10.7326/M14-2693](#)]
- 62 **Hensley-McBain T**, Zevin AS, Manuzak J, Smith E, Gile J, Miller C, Agricola B, Katze M, Reeves RK, Kraft CS, Langevin S, Klatt NR. Effects of Fecal Microbial Transplantation on Microbiome and Immunity in Simian Immunodeficiency Virus-Infected Macaques. *J Virol* 2016; **90**: 4981-4989 [PMID: [26937040](#) DOI: [10.1128/JVI.00099-16](#)]
- 63 **Xu Y**, Li X, Zhu B, Liang H, Fang C, Gong Y, Guo Q, Sun X, Zhao D, Shen J, Zhang H, Liu H, Xia H, Tang J, Zhang K, Gong S. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat Med* 2020; **26**: 502-505 [PMID: [32284613](#) DOI: [10.1038/s41591-020-0817-4](#)]
- 64 **Alang N**, Kelly CR. Weight gain after fecal microbiota transplantation. *Open Forum Infect Dis* 2015; **2**: ofv004 [PMID: [26034755](#) DOI: [10.1093/ofid/ofv004](#)]
- 65 **Monaghan TM**, Seekatz AM, Markham NO, Yau TO, Hatzia Apostolou M, Jilani T, Christodoulou N, Roach B, Birli E, Pomenya O, Louie T, Lacy DB, Kim P, Lee C, Kao D, Polytarchou C. Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Associates With Functional Alterations in Circulating microRNAs. *Gastroenterology* 2021; **161**: 255-270.e4 [PMID: [33844988](#) DOI: [10.1053/j.gastro.2021.03.050](#)]
- 66 **Monaghan TM**, Duggal NA, Rosati E, Griffin R, Hughes J, Roach B, Yang DY, Wang C, Wong K, Saxinger L, Pučić-Baković M, Vučković F, Klicek F, Lauc G, Tighe P, Mullish BH, Blanco JM, McDonald JAK, Marchesi JR, Xue N, Dottorini T, Acharjee A, Franke A, Li Y, Wong GK, Polytarchou C, Yau TO, Christodoulou N, Hatzia Apostolou M, Wang M, Russell LA, Kao DH. A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection. *Cells* 2021; **10** [PMID: [34831456](#) DOI: [10.3390/cells10113234](#)]
- 67 **Yau TO**, Wu CW, Dong Y, Tang CM, Ng SS, Chan FK, Sung JJ, Yu J. microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. *Br J Cancer* 2014; **111**: 1765-1771 [PMID: [25233396](#) DOI: [10.1038/bjc.2014.484](#)]
- 68 **Yau TO**, Wu CW, Tang CM, Chen Y, Fang J, Dong Y, Liang Q, Ng SS, Chan FK, Sung JJ, Yu J. MicroRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer. *Oncotarget* 2016; **7**: 1559-1568 [PMID: [26621842](#) DOI: [10.18632/oncotarget.6403](#)]
- 69 **Yau TO**, Tang CM, Harriss EK, Dickins B, Polytarchou C. Faecal microRNAs as a non-invasive tool in the diagnosis of colonic adenomas and colorectal cancer: A meta-analysis. *Sci Rep* 2019; **9**: 9491 [PMID: [31263200](#) DOI: [10.1038/s41598-019-45570-9](#)]
- 70 **Deak E**, Miller SA, Humphries RM. Comparison of Illumigene, Simplexa, and AmpliVue Clostridium difficile molecular assays for diagnosis of C. difficile infection. *J Clin Microbiol* 2014; **52**: 960-963 [PMID: [24352999](#) DOI: [10.1128/JCM.02354-13](#)]
- 71 **Juretschko S**, Manji R, Khare R, Das S, Dunbar S. Performance Evaluation of the Luminex Aries C. difficile Assay in Comparison to Two Other Molecular Assays within a Multihospital Health Care Center. *J Clin Microbiol* 2019; **57** [PMID: [31413082](#) DOI: [10.1128/JCM.01092-19](#)]
- 72 **Pancholi P**, Young S, Widen R, Silbert S, Schmitt B, Dunn R, Drain A, Weissfeld SA. A multicenter evaluation of a sample to answer real-time PCR assay for toxigenic C. difficile in symptomatic subjects. *Diagn Microbiol Infect Dis* 2020; **96**: 114920 [PMID: [31699545](#) DOI: [10.1016/j.diagmicrobio.2019.114920](#)]
- 73 **Jazmati N**, Wiegand P, Ličanin B, Plum G. Evaluation of the Qiagen artus C. difficile QS-RGQ Kit for Detection of Clostridium difficile Toxins A and B in Clinical Stool Specimens. *J Clin Microbiol* 2015; **53**: 1942-1944 [PMID: [25809977](#) DOI: [10.1128/JCM.00613-15](#)]
- 74 **Hirvonen JJ**, Kaukoranta SS. Comparison of BD Max Cdiff and GenomEra C. difficile molecular assays for detection of toxigenic Clostridium difficile from stools in conventional sample containers and in FecalSwabs. *Eur J Clin Microbiol Infect Dis* 2015; **34**: 1005-1009 [PMID: [25616552](#) DOI: [10.1007/s10096-015-2320-2](#)]
- 75 **Dalpe AH**, Hofko M, Zorn M, Zimmermann S. Evaluation of the fully automated BD MAX Cdiff and Xpert C. difficile assays for direct detection of Clostridium difficile in stool specimens. *J Clin Microbiol* 2013; **51**: 1906-1908 [PMID: [23515539](#) DOI: [10.1128/JCM.00344-13](#)]
- 76 **Stellrecht KA**, Espino AA, Maceira VP, Nattanmai SM, Butt SA, Wroblewski D, Hannett GE, Musser KA. Premarket evaluations of the IMDx C. difficile for Abbott m2000 Assay and the BD Max Cdiff Assay. *J Clin Microbiol* 2014; **52**: 1423-1428 [PMID: [24554744](#) DOI: [10.1128/JCM.03293-13](#)]
- 77 **Shin BM**, Yoo SM, Shin WC. Evaluation of Xpert C. difficile, BD MAX Cdiff, IMDx C. difficile for Abbott m2000, and Illumigene C. difficile Assays for Direct Detection of Toxigenic Clostridium difficile in Stool Specimens. *Ann Lab Med* 2016; **36**: 131-137 [PMID: [26709260](#) DOI: [10.3343/alm.2016.36.2.131](#)]
- 78 **Terhes G**, Urbán E, Sóni J, Nacs E, Nagy E. Comparison of a rapid molecular method, the BD GeneOhm Cdiff assay, to the most frequently used laboratory tests for detection of toxin-producing Clostridium difficile in diarrheal feces. *J Clin Microbiol* 2009; **47**: 3478-3481 [PMID: [19794052](#) DOI: [10.1128/JCM.01133-09](#)]
- 79 **Stamper PD**, Alcabasa R, Aird D, Babiker W, Wehrin J, Ikpeama I, Carroll KC. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. *J Clin Microbiol* 2009; **47**: 373-378 [PMID: [19073875](#) DOI: [10.1128/JCM.01613-08](#)]
- 80 **Kvach EJ**, Ferguson D, Riska PF, Landry ML. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. *J Clin Microbiol* 2010; **48**: 109-114 [PMID: [19864479](#) DOI: [10.1128/JCM.01630-09](#)]

- 81 **Karre T**, Sloan L, Patel R, Mandrekar J, Rosenblatt J. Comparison of two commercial molecular assays to a laboratory-developed molecular assay for diagnosis of *Clostridium difficile* infection. *J Clin Microbiol* 2011; **49**: 725-727 [PMID: 21123537 DOI: 10.1128/JCM.01028-10]
- 82 **Shin BM**, Mun SJ, Yoo SJ, Kuak EY. Comparison of BD GeneOhm Cdiff and Seegene Seeplex ACE PCR assays using toxigenic *Clostridium difficile* culture for direct detection of *tcdB* from stool specimens. *J Clin Microbiol* 2012; **50**: 3765-3767 [PMID: 22952270 DOI: 10.1128/JCM.01440-12]
- 83 **Garg SK**, Lu K, Duncan J, Peterson LR, Liesenfeld O. Equivalent Performance of the Cobas® Cdiff Test for Use on the Cobas® Liat® System and the Cobas® 4800 System. *Eur J Microbiol Immunol (Bp)* 2017; **7**: 310-318 [PMID: 29403660 DOI: 10.1556/1886.2017.00034]
- 84 **Peterson LR**, Young SA, Davis TE Jr, Wang ZX, Duncan J, Noutsios C, Liesenfeld O, Osiecki JC, Lewinski MA. Evaluation of the cobas Cdiff Test for Detection of Toxigenic *Clostridium difficile* in Stool Samples. *J Clin Microbiol* 2017; **55**: 3426-3436 [PMID: 28954901 DOI: 10.1128/JCM.01135-17]
- 85 **Mashock MJ**, Faron ML, Carroll KC, Dang C, Lewis S, Salimnia H, Lephart P, Loo VG, Schmitt BH, Young S, Buchan BW, Ledebor NA. A Multicenter Study of the Revogene C. difficile System for Detection of the Toxin B Gene from Unformed Stool Specimens. *J Clin Microbiol* 2020; **58** [PMID: 31776191 DOI: 10.1128/JCM.01510-19]
- 86 **U. S. Food and Drug Administration.** 510(k) Summary ICEPlex C. difficile Kit on the ICEPlex System 2013. Available from: <https://www.fda.gov/>
- 87 **Buchan BW**, Mackey TL, Daly JA, Alger G, Denys GA, Peterson LR, Kehl SC, Ledebor NA. Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic *Clostridium difficile* strains in clinical stool specimens. *J Clin Microbiol* 2012; **50**: 3932-3936 [PMID: 23015667 DOI: 10.1128/JCM.02083-12]
- 88 **Denys GA.** Portrait Toxigenic *Clostridium difficile* assay, an isothermal amplification assay detects toxigenic C. difficile in clinical stool specimens. *Expert Rev Mol Diagn* 2014; **14**: 17-26 [PMID: 24308336 DOI: 10.1586/14737159.2014.864239]
- 89 **Stamper PD**, Babiker W, Alcabasa R, Aird D, Wehrin J, Ikpeama I, Gluck L, Carroll KC. Evaluation of a new commercial TaqMan PCR assay for direct detection of the *clostridium difficile* toxin B gene in clinical stool specimens. *J Clin Microbiol* 2009; **47**: 3846-3850 [PMID: 19846637 DOI: 10.1128/JCM.01490-09]
- 90 **Beck ET**, Buchan BW, Riebe KM, Alkins BR, Pancholi P, Granato PA, Ledebor NA. Multicenter evaluation of the Quidel Lyra Direct C. difficile nucleic acid amplification assay. *J Clin Microbiol* 2014; **52**: 1998-2002 [PMID: 24671790 DOI: 10.1128/JCM.03089-13]
- 91 **Gilbreath JJ**, Verma P, Abbott AN, Butler-Wu SM. Comparison of the Verigene *Clostridium difficile*, Simplexa C. difficile Universal Direct, BD MAX Cdiff, and Xpert C. difficile assays for the detection of toxigenic C. difficile. *Diagn Microbiol Infect Dis* 2014; **80**: 13-18 [PMID: 25027069 DOI: 10.1016/j.diagmicrobio.2014.06.001]
- 92 **U. S. Food and Drug Administration.** 510(K) Substantial Equivalence Determination Decision Summary Assay and Instrument Combination Template 2018. Available from: https://www.baidu.com/link?url=bxZ2qu2ujOxmV4JObS_gYXHE5P8RRA1m4gfponKdX2KcgYUD6hwTI2h16v_7mP6lA3faJYql3jOpwCrN7NcpQPR98wNFSfu76enVjhfx2a&wd=&eqid=ae7ede620006e9e8000000066447ba8e
- 93 **Carroll KC**, Buchan BW, Tan S, Stamper PD, Riebe KM, Pancholi P, Kelly C, Rao A, Fader R, Cavagnolo R, Watson W, Goering RV, Trevino EA, Weissfeld AS, Ledebor NA. Multicenter evaluation of the Verigene *Clostridium difficile* nucleic acid assay. *J Clin Microbiol* 2013; **51**: 4120-4125 [PMID: 24088862 DOI: 10.1128/JCM.01690-13]
- 94 **Kosai K**, Iwanaga Y, Akamatsu N, Okada Y, Kaku N, Uno N, Morinaga Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K. Performance evaluation of the Verigene® *Clostridium difficile* nucleic acid test, an automated multiplex molecular testing system for detection of C. difficile toxin. *J Infect Chemother* 2017; **23**: 674-677 [PMID: 28751156 DOI: 10.1016/j.jiac.2017.07.002]
- 95 **Bai Y**, Sun X, Jin Y, Wang Y, Li J. Accuracy of Xpert *Clostridium difficile* assay for the diagnosis of *Clostridium difficile* infection: A meta analysis. *PloS One* 2017; **12**: e0185891 [PMID: 29016644 DOI: 10.1371/journal.pone.0185891]
- 96 **Moon HW**, Kim HN, Hur M, Shim HS, Kim H, Yun YM. Comparison of Diagnostic Algorithms for Detecting Toxigenic *Clostridium difficile* in Routine Practice at a Tertiary Referral Hospital in Korea. *PloS One* 2016; **11**: e0161139 [PMID: 27532104 DOI: 10.1371/journal.pone.0161139]
- 97 **Eastwood K**, Else P, Charlett A, Wilcox M. Comparison of nine commercially available *Clostridium difficile* toxin detection assays, a real-time PCR assay for C. difficile *tcdB*, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. *J Clin Microbiol* 2009; **47**: 3211-3217 [PMID: 19710274 DOI: 10.1128/JCM.01082-09]
- 98 **O'Connor D**, Hynes P, Cormican M, Collins E, Corbett-Feeney G, Cassidy M. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* 2001; **39**: 2846-2849 [PMID: 11474001 DOI: 10.1128/JCM.39.8.2846-2849.2001]
- 99 **Drudy D**, Harnedy N, Fanning S, O'Mahony R, Kyne L. Isolation and characterisation of toxin A-negative, toxin B-positive *Clostridium difficile* in Dublin, Ireland. *Clin Microbiol Infect* 2007; **13**: 298-304 [PMID: 17391385 DOI: 10.1111/j.1469-0691.2006.01634.x]
- 100 **Planche TD**, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, O'Connor L, Oakley SJ, Pope CF, Wren MW, Shetty NP, Crook DW, Wilcox MH. Differences in outcome according to *Clostridium difficile* testing method: a prospective multicentre diagnostic validation study of C difficile infection. *Lancet Infect Dis* 2013; **13**: 936-945 [PMID: 24007915 DOI: 10.1016/S1473-3099(13)70200-7]
- 101 **Novak-Weekley SM**, Marlowe EM, Miller JM, Cumpio J, Nomura JH, Vance PH, Weissfeld A. *Clostridium difficile* testing in the clinical laboratory by use of multiple testing algorithms. *J Clin Microbiol* 2010; **48**: 889-893 [PMID: 20071552 DOI: 10.1128/JCM.01801-09]
- 102 **Barkin JA**, Nandi N, Miller N, Grace A, Barkin JS, Sussman DA. Superiority of the DNA amplification assay for the diagnosis of C. difficile infection: a clinical comparison of fecal tests. *Dig Dis Sci* 2012; **57**: 2592-2599 [PMID: 22576711 DOI: 10.1007/s10620-012-2200-x]
- 103 **Babady NE**, Stiles J, Ruggiero P, Khosa P, Huang D, Shuptar S, Kamboj M, Kiehn TE. Evaluation of the Cepheid Xpert

- Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. *J Clin Microbiol* 2010; **48**: 4519-4524 [PMID: 20943860 DOI: 10.1128/JCM.01648-10]
- 104 **Leitner E**, Einetter M, Grisold AJ, Marth E, Feierl G. Evaluation of the BD MAX Cdiff assay for the detection of the toxin B gene of Clostridium difficile out of faecal specimens. *Diagn Microbiol Infect Dis* 2013; **76**: 390-391 [PMID: 23602785 DOI: 10.1016/j.diagmicrobio.2013.03.007]
- 105 **Ota KV**, McGowan KL. Clostridium difficile testing algorithms using glutamate dehydrogenase antigen and C. difficile toxin enzyme immunoassays with C. difficile nucleic acid amplification testing increase diagnostic yield in a tertiary pediatric population. *J Clin Microbiol* 2012; **50**: 1185-1188 [PMID: 22259201 DOI: 10.1128/JCM.05620-11]
- 106 **van den Berg RJ**, Vaessen N, Endtz HP, Schölin T, van der Vorm ER, Kuijper EJ. Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study. *J Med Microbiol* 2007; **56**: 36-42 [PMID: 17172514 DOI: 10.1099/jmm.0.46680-0]
- 107 **Vanpoucke H**, De Baere T, Claeys G, Vaneechoutte M, Verschraegen G. Evaluation of six commercial assays for the rapid detection of Clostridium difficile toxin and/or antigen in stool specimens. *Clin Microbiol Infect* 2001; **7**: 55-64 [PMID: 11298143 DOI: 10.1046/j.1469-0691.2001.00141.x]
- 108 **Mattner F**, Winterfeld I, Mattner L. Diagnosing toxigenic Clostridium difficile: new confidence bounds show culturing increases sensitivity of the toxin A/B enzyme immunoassay and refute gold standards. *Scand J Infect Dis* 2012; **44**: 578-585 [PMID: 22404319 DOI: 10.3109/00365548.2012.655772]
- 109 **Musher DM**, Manhas A, Jain P, Nuila F, Waqar A, Logan N, Marino B, Graviss EA. Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay. *J Clin Microbiol* 2007; **45**: 2737-2739 [PMID: 17567791 DOI: 10.1128/JCM.00686-07]
- 110 **Snell H**, Ramos M, Longo S, John M, Hussain Z. Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea. *J Clin Microbiol* 2004; **42**: 4863-4865 [PMID: 15472364 DOI: 10.1128/JCM.42.10.4863-4865.2004]
- 111 **Massey V**, Gregson DB, Chagla AH, Storey M, John MA, Hussain Z. Clinical usefulness of components of the Triage immunoassay, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture assay for the diagnosis of Clostridium difficile diarrhea. *Am J Clin Pathol* 2003; **119**: 45-49 [PMID: 12520696 DOI: 10.1309/U8AT-L52Q-60XY-AVX6]
- 112 **Bruins MJ**, Verbeek E, Wallinga JA, Bruijnesteijn van Coppenraet LE, Kuijper EJ, Bloembergen P. Evaluation of three enzyme immunoassays and a loop-mediated isothermal amplification test for the laboratory diagnosis of Clostridium difficile infection. *Eur J Clin Microbiol Infect Dis* 2012; **31**: 3035-3039 [PMID: 22706512 DOI: 10.1007/s10096-012-1658-y]
- 113 **Sloan LM**, Duresko BJ, Gustafson DR, Rosenblatt JE. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. *J Clin Microbiol* 2008; **46**: 1996-2001 [PMID: 18434563 DOI: 10.1128/JCM.00032-08]
- 114 **Hart J**, Putsathit P, Knight DR, Samuels L, Riley TV, Keil A. Clostridium difficile infection diagnosis in a paediatric population: comparison of methodologies. *Eur J Clin Microbiol Infect Dis* 2014; **33**: 1555-1564 [PMID: 24781004 DOI: 10.1007/s10096-014-2108-9]
- 115 **Kawada M**, Annaka M, Kato H, Shibasaki S, Hikosaka K, Mizuno H, Masuda Y, Inamatsu T. Evaluation of a simultaneous detection kit for the glutamate dehydrogenase antigen and toxin A/B in feces for diagnosis of Clostridium difficile infection. *J Infect Chemother* 2011; **17**: 807-811 [PMID: 21725661 DOI: 10.1007/s10156-011-0267-5]
- 116 **Swindells J**, Brenwald N, Reading N, Oppenheim B. Evaluation of diagnostic tests for Clostridium difficile infection. *J Clin Microbiol* 2010; **48**: 606-608 [PMID: 20032256 DOI: 10.1128/JCM.01579-09]
- 117 **Kim H**, Kim WH, Kim M, Jeong SH, Lee K. Evaluation of a rapid membrane enzyme immunoassay for the simultaneous detection of glutamate dehydrogenase and toxin for the diagnosis of Clostridium difficile infection. *Ann Lab Med* 2014; **34**: 235-239 [PMID: 24790912 DOI: 10.3343/alm.2014.34.3.235]
- 118 **de Boer RF**, Wijma JJ, Schuurman T, Moedt J, Dijk-Alberts BG, Ott A, Kooistra-Smid AM, van Duynhoven YT. Evaluation of a rapid molecular screening approach for the detection of toxigenic Clostridium difficile in general and subsequent identification of the tcdC Δ117 mutation in human stools. *J Microbiol Methods* 2010; **83**: 59-65 [PMID: 20674616 DOI: 10.1016/j.mimet.2010.07.017]
- 119 **Yoldaş Ö**, Altundış M, Cufalı D, Aşık G, Keşli R. A Diagnostic Algorithm for the Detection of Clostridium difficile-Associated Diarrhea. *Balkan Med J* 2016; **33**: 80-86 [PMID: 26966622 DOI: 10.5152/balkanmedj.2015.15159]
- 120 **Le Guern R**, Herwegh S, Grandbastien B, Courcol R, Wallet F. Evaluation of a new molecular test, the BD Max Cdiff, for detection of toxigenic Clostridium difficile in fecal samples. *J Clin Microbiol* 2012; **50**: 3089-3090 [PMID: 22760042 DOI: 10.1128/JCM.01250-12]
- 121 **Reller ME**, Alcabasa RC, Lema CA, Carroll KC. Comparison of two rapid assays for Clostridium difficile Common antigen and a C difficile toxin A/B assay with the cell culture neutralization assay. *Am J Clin Pathol* 2010; **133**: 107-109 [PMID: 20023265 DOI: 10.1309/AJCPO3QWOU8CYGEU]
- 122 **Benedek O**, Podbielski A, Warnke P. Laboratory Experience with the Liaison Analyzer in the Diagnosis of Clostridium Difficile-Associated Diarrhea. *Eur J Microbiol Immunol (Bp)* 2016; **6**: 215-218 [PMID: 27766170 DOI: 10.1556/1886.2016.00017]
- 123 **Makrithatis A**, Zeller I, Mitteregger D, Kundi M, Hirschl AM. Comprehensive evaluation of chemiluminescent immunoassays for the laboratory diagnosis of Clostridium difficile infection. *Eur J Clin Microbiol Infect Dis* 2017; **36**: 1253-1259 [PMID: 28181032 DOI: 10.1007/s10096-017-2916-9]
- 124 **Shin BM**, Kuak EY, Lee EJ, Songer JG. Algorithm combining toxin immunoassay and stool culture for diagnosis of Clostridium difficile infection. *J Clin Microbiol* 2009; **47**: 2952-2956 [PMID: 19625481 DOI: 10.1128/JCM.00609-09]
- 125 **Shin BM**, Lee EJ, Kuak EY, Yoo SJ. Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area. *Anaerobe* 2009; **15**: 266-269 [PMID: 19772927 DOI: 10.1016/j.anaerobe.2009.09.008]

- 126 **Kim H**, Jeong SH, Kim M, Lee Y, Lee K. Detection of Clostridium difficile toxin A/B genes by multiplex real-time PCR for the diagnosis of *C. difficile* infection. *J Med Microbiol* 2012; **61**: 274-277 [PMID: [21959205](#) DOI: [10.1099/jmm.0.035618-0](#)]
- 127 **Shin S**, Kim M, Lim H, Kim H, Lee K, Chong Y. Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection. *Ann Lab Med* 2012; **32**: 355-358 [PMID: [22950071](#) DOI: [10.3343/alm.2012.32.5.355](#)]
- 128 **de Jong E**, de Jong AS, Bartels CJ, van der Rijt-van den Biggelaar C, Melchers WJ, Sturm PD. Clinical and laboratory evaluation of a real-time PCR for Clostridium difficile toxin A and B genes. *Eur J Clin Microbiol Infect Dis* 2012; **31**: 2219-2225 [PMID: [22327373](#) DOI: [10.1007/s10096-012-1558-1](#)]
- 129 **Shin BM**, Lee EJ, Moon JW, Lee SY. Evaluation of the VIDAS glutamate dehydrogenase assay for the detection of Clostridium difficile. *Anaerobe* 2016; **40**: 68-72 [PMID: [27282799](#) DOI: [10.1016/j.anaerobe.2016.06.001](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

